DataVXJournal of Nanoparticle ResearchPaper
journal article·2024-12

Direct introduction of cationic and anionic lipids to create pH-sensitive charge-reversible liposomes with optimized pharmacokinetics and antitumor effects

Ziming Lin, Hanwen Zhu, Xiaobang Liu, Pingyu Liu, Miao Hu, Panting Wan, Minzhen Dong, Li Zhang, Huae Xu, Yijun Wang

Journal of Nanoparticle Research· Volume 26· Issue 12
Publisher page
Bibliographic record

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (38)

Show source-provided references
1. Souri M, Soltani M, Kashkooli FM, Shahvandi MK (2021) Engineered strategies to enhance tumor penetration of drug-loaded nanoparticles. J Control Release 341:227–246. https://doi.org/10.1016/j.jconrel.2021.11.02410.1016/j.jconrel.2021.11.024 ↗
2. Yang H, Tong Z, Sun S, Mao Z (2020) Enhancement of tumour penetration by nanomedicines through strategies based on transport processes and barriers. J Control Release 328:28–44. https://doi.org/10.1016/j.jconrel.2020.08.02410.1016/j.jconrel.2020.08.024 ↗
3. Ding J, Chen J, Gao L, Jiang Z, Zhang Y, Li M, Xiao Q, Lee SS, Chen X (2019) Engineered nanomedicines with enhanced tumor penetration. Nano Today 29:100800. https://doi.org/10.1016/j.nantod.2019.10080010.1016/j.nantod.2019.100800 ↗
4. Wang S, Liu L, Tian L, Xu P, Li S, Hu L, Xia Y, Ding Y, Wang J, Li S (2024) Elucidation of spatial cooperativity in chemo-immunotherapy by a sequential dual-pH-responsive drug delivery system. Adv Mater 36(26):2403296. https://doi.org/10.1002/adma.20240329610.1002/adma.202403296 ↗
5. Yuan G, Li M, Zhang Y, Dong Q, Shao S, Zhou Z, Tang J, Xiang J, Shen Y (2024) Modulating intracellular dynamics for optimized intracellular release and transcytosis equilibrium. Adv Mater 36(25):2400425. https://doi.org/10.1002/adma.20240042510.1002/adma.202400425 ↗
6. Wang Q, Liu J, Liu J, Thant Y, Weng W, Wei C, Bao R, Adu-Frimpong M, Yu Q, Deng W, Cao X, Toreniyazov E, Ji H, Xu X, Yu J (2021) Bisdemethoxycurcumin-conjugated vitamin E TPGS liposomes ameliorate poor bioavailability of free form and evaluation of its analgesic and hypouricemic activity in oxonate-treated rats. J Nanopart Res 23(1–16):122. https://doi.org/10.1007/s11051-021-05222-410.1007/s11051-021-05222-4 ↗
7. Yim H, Park SJ, Bae YH, Na K (2013) Biodegradable cationic nanoparticles loaded with an anticancer drug for deep penetration of heterogeneous tumours. Biomaterials 34(31):7674–7682. https://doi.org/10.1016/j.biomaterials.2013.06.05810.1016/j.biomaterials.2013.06.058 ↗
8. Yu YF, Wu EC, Lin SQ, Chu YX, Yang Y, Pan F, Ding TH, Qian J, Jiang K, Zhan CY (2024) Reexamining the effects of drug loading on the in vivo performance of PEGylated liposomal doxorubicin. Acta Pharmacol Sin 45(3):646–659. https://doi.org/10.1038/s41401-023-01169-510.1038/s41401-023-01169-5 ↗
9. Nguyen LNM, Lin ZP (2023) The exit of nanoparticles from solid tumours. Nat Mater 22(10):1261–1272. https://doi.org/10.1038/s41563-023-01630-010.1038/s41563-023-01630-0 ↗
10. Nguyen LNM, Ngo W, Lin ZP, Sindhwani S, MacMillan P, Mladjenovic SM, Chan WCW (2024) The mechanisms of nanoparticle delivery to solid tumours. Nat Rev Bioeng 2:201–213. https://doi.org/10.1038/s44222-024-00154-910.1038/s44222-024-00154-9 ↗
11. Tanzadehpanah H, Mahaki H, Manoochehri H, Soleimani M, Najafi R (2022) AS1411 aptamer improves therapeutic efficacy of PEGylated nanoliposomes loaded with gefitinib in the mice bearing CT26 colon carcinoma. J Nanopart Res 24(12):1–18. https://doi.org/10.1007/s11051-022-05630-010.1007/s11051-022-05630-0 ↗
12. Huo D, Jiang X, Hu Y (2020) Recent advances in nanostrategies capable of overcoming biological barriers for tumor management. Adv Mater 32(27):e1904337. https://doi.org/10.1002/adma.20190433710.1002/adma.201904337 ↗
13. Li Y, Yuan R, Luo Y, Guo X, Yang G, Li X, Zhou S (2023) A hierarchical structured fiber device remodeling the acidic tumor microenvironment for enhanced cancer immunotherapy. Adv Mater 35(21):e2300216. https://doi.org/10.1002/adma.20230021610.1002/adma.202300216 ↗
14. Zhou Q, Xiang J (2023) Tumor abnormality-oriented nanomedicine design. Chem Rev 123(18):10920–10989. https://doi.org/10.1021/acs.chemrev.3c0006210.1021/acs.chemrev.3c00062 ↗
15. Zhou L, Zhang P (2020) Smart nanosized drug delivery systems inducing immunogenic cell death for combination with cancer immunotherapy. Acc Chem Res 53(9):1761–1772. https://doi.org/10.1021/acs.accounts.0c0025410.1021/acs.accounts.0c00254 ↗
16. Kanamala M, Wilson WR, Yang M, Palmer BD, Wu Z (2016) Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review. Biomaterials 85:152–167. https://doi.org/10.1016/j.biomaterials.2016.01.06110.1016/j.biomaterials.2016.01.061 ↗
17. Dai Y, Xu C, Sun X, Chen X (2017) Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chem Soc Rev 46(12):3830–3852. https://doi.org/10.1039/c6cs00592f10.1039/c6cs00592f ↗
18. Wang S, Huang P, Chen X (2016) Stimuli-responsive programmed specific targeting in nanomedicine. ACS Nano 10(3):2991–3004. https://doi.org/10.1021/acsnano.6b0087010.1021/acsnano.6b00870 ↗
19. Wang Z, Sun Y, Shen Y, Zhou Z (2024) Stimuli-responsive nanocarriers for transcytosis-based cancer drug delivery. Adv NanoBiomed Res 4(3):2300125. https://doi.org/10.1002/anbr.20230012510.1002/anbr.202300125 ↗
20. Reimhult E, Virk MM (2021) Hybrid lipopolymer vesicle drug delivery and release systems. J Biomed Res 35(4):301–309. https://doi.org/10.7555/JBR.35.2020020610.7555/JBR.35.20200206 ↗
21. Feng T, Ai X, An G, Yang P, Zhao Y (2016) Charge-convertible carbon dots for imaging-guided drug delivery with enhanced in vivo cancer therapeutic efficiency. ACS Nano 10(4):4410–4420. https://doi.org/10.1021/acsnano.6b0004310.1021/acsnano.6b00043 ↗
22. Sun CY, Shen S, Xu CF, Li HJ, Liu Y, Cao ZT, Yang XZ, Xia JX, Wang J (2015) Tumor acidity-sensitive polymeric vector for active targeted siRNA delivery. J Am Chem Soc 137(48):15217–15224. https://doi.org/10.1021/jacs.5b0960210.1021/jacs.5b09602 ↗
23. Chang Y, Huang Z, Jiao Y, Xu JF, Zhang X (2018) pH-induced charge-reversal amphiphile with cancer cell-selective membrane-disrupting activity. ACS Appl Mater Interfaces 10(25):21191–21197. https://doi.org/10.1021/acsami.8b0666010.1021/acsami.8b06660 ↗
24. Zhang T, Song X, Kang D, Zhang L, Zhang C, Jin S, Wang C, Tian J, Xing J, Liang XJ (2015) Modified bovine serum albumin as an effective charge-reversal platform for simultaneously improving the transfection efficiency and biocompatibility of polyplexes. J Mater Chem B 3(23):4698–4706. https://doi.org/10.1039/c5tb00548e10.1039/c5tb00548e ↗
25. Sun Q, Zhou Z, Qiu N, Shen Y (2017) Rational design of cancer nanomedicine: nanoproperty integration and synchronization. Adv Mater 29(14):1606628. https://doi.org/10.1002/adma.20160662810.1002/adma.201606628 ↗
26. Huang Y, Tang Z, Zhang X, Yu H, Sun H, Pang X, Chen X (2013) pH-Triggered charge-reversal polypeptide nanoparticles for cisplatin delivery: preparation and in vitro evaluation. Biomacromol 14(6):2023–2032. https://doi.org/10.1021/bm400358z10.1021/bm400358z ↗
27. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R (2020) Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 20(2):101–124. https://doi.org/10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
28. Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA (2021) Targeted drug delivery strategies for precision medicines. Nat Rev Mater 6:351–370. https://doi.org/10.1038/s41578-020-00269-610.1038/s41578-020-00269-6 ↗
29. Huang R, Zhou P, Chen B, Zhu Y (2023) Stimuli-responsive nanoadjuvant rejuvenates robust immune responses to sensitize cancer immunotherapy. ACS Nano 17(21):21455–21469. https://doi.org/10.1021/acsnano.3c0623310.1021/acsnano.3c06233 ↗
30. Jin MZ, Jin WL (2020) The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther 5(1):166. https://doi.org/10.1038/s41392-020-00280-x10.1038/s41392-020-00280-x ↗
31. Weiss-Steider B, Marcelín-Jiménez G, Soto-Vázquez R, Reyes-Rodríguez AN, Rangel-Corona R, Vargas-Ángeles CA, Corona-Ortega MT (2024) Design of a liposome with the property to induce CD16 on cervical cancer cells with a purified spermidine-cholesterol. J Nanopart Res 26(2):27. https://doi.org/10.1007/s11051-023-05913-010.1007/s11051-023-05913-0 ↗
32. Zhao Y, Li J, Yu H, Wang G, Liu W (2012) Synthesis and characterization of a novel polydepsipeptide contained tri-block copolymer (mPEG–PLLA–PMMD) as self-assembly micelle delivery system for paclitaxel. Int J Pharm 430(1):282–291. https://doi.org/10.1016/j.ijpharm.2012.03.04310.1016/j.ijpharm.2012.03.043 ↗
33. Lin Z, Deng T, Liu Y, Zheng S, Wang G, He H, Zhang J (2023) Comprehensive analysis of the influence of physicochemical properties and tumor-associated environments on liposome intratumoral penetration. J Control Release 359:33–51. https://doi.org/10.1016/j.jconrel.2023.05.02710.1016/j.jconrel.2023.05.027 ↗
34. Liu J, Yan F, Chen H, Wang W, Liu W, Hao K, Wang G, Zhou F, Zhang J (2017) A novel individual-cell-based mathematical model based on multicellular tumour spheroids for evaluating doxorubicin-related delivery in avascular regions. Br J Pharmacol 174(17):2862–2879. https://doi.org/10.1111/bph.1390910.1111/bph.13909 ↗
35. Waghray D, Zhang Q (2018) Inhibit or evade multidrug resistance P-glycoprotein in cancer treatment. J Med Chem 61(12):5108–5121. https://doi.org/10.1021/acs.jmedchem.7b0145710.1021/acs.jmedchem.7b01457 ↗
36. Liu M, Huang L, Zhang W, Wang X, Geng Y, Zhang Y, Wang L, Zhang W, Zhang Y-J, Xiao S, Bao Y, Xiong M, Wang J (2022) A transistor-like pH-sensitive nanodetergent for selective cancer therapy. Nat Nanotechnol 17(5):541–551. https://doi.org/10.1038/s41565-022-01085-510.1038/s41565-022-01085-5 ↗
37. Hartshorn CM, Bradbury MS (2018) Nanotechnology strategies to advance outcomes in clinical cancer care. ACS Nano 12(1):24–43. https://doi.org/10.1021/acsnano.7b0510810.1021/acsnano.7b05108 ↗
38. Sakamoto K, Schmidt JW, Wagner KU (2015) Mouse models of breast cancer. Methods Mol Biol 1267:47–71. https://doi.org/10.1007/978-1-4939-2297-0_310.1007/978-1-4939-2297-0_3 ↗